PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR ANTAGONIST USE FOR NSTEACS: A REVIEW TO PATIENT SELECTION
| العنوان بلغة أخرى: |
دراسة لتحديد المرضى الأكثر استفادة من مضادات مستقبلات البروتين السكري 2ب/3أ في حالات القصور الحاد بالشرايين التاجية غير المصحوب بارتفاع قطعة إس تي. |
|---|---|
| المؤلف الرئيسي: | Mohammed Farhat, Ahmed |
| مؤلفين آخرين: | Ahmed Ibrahim Nassar, Amr Adel El Sayed (مشرف) |
| التاريخ الميلادي: |
2010
|
| الصفحات: | 198 |
| نوع المحتوى: | رسائل جامعية |
| اللغة: | الإنجليزية |
| الدرجة العلمية | رسالة ماجستير |
| الجامعة | Faculty of medicine / Ain Shams University/Cardiology |
| الدولة | مصر |
| المصدر: | غير محدد |
| الحالة | تمت المناقشة |
| قواعد المعلومات: | Thesis |
| المستخلص: | The aim of this study is to compare patients of NSTEACS (at low or intermediate risk) who were given GP IIb/IIIa antagonist (Tirofiban) and those who were not; to evaluate benefits gained both angiographically and clinically ( major adverse cardiac events |
| الوصف | The aim of this study is to compare patients of NSTEACS (at low or intermediate risk) who were given GP IIb/IIIa antagonist (Tirofiban) and those who were not; to evaluate benefits gained both angiographically and clinically ( major adverse cardiac events |
| LEADER | 01271nam a2200253Ia 4500 | ||
|---|---|---|---|
| 001 | 1549385 | ||
| 040 | |a غير محدد | ||
| 041 | |a eng | ||
| 100 | |a Mohammed Farhat, Ahmed |e معد | ||
| 245 | |a PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR ANTAGONIST USE FOR NSTEACS: A REVIEW TO PATIENT SELECTION | ||
| 246 | |a دراسة لتحديد المرضى الأكثر استفادة من مضادات مستقبلات البروتين السكري 2ب/3أ في حالات القصور الحاد بالشرايين التاجية غير المصحوب بارتفاع قطعة إس تي. | ||
| 260 | |c 2010 | ||
| 300 | |a 198 | ||
| 336 | |a رسائل جامعية | ||
| 502 | |b رسالة ماجستير | ||
| 502 | |c Faculty of medicine / Ain Shams University/Cardiology | ||
| 502 | |g مصر | ||
| 520 | |a The aim of this study is to compare patients of NSTEACS (at low or intermediate risk) who were given GP IIb/IIIa antagonist (Tirofiban) and those who were not; to evaluate benefits gained both angiographically and clinically ( major adverse cardiac events | ||
| 653 | |a Acute coronary syndromes- | ||
| 700 | |a Ahmed Ibrahim Nassar |e مشرف | ||
| 700 | |a Amr Adel El Sayed |e مشرف | ||
| 940 | |a تمت المناقشة | ||
| 995 | |a Thesis | ||
| 999 | |c 270350 |d 270350 | ||
عناصر مشابهة
-
Value of Glycoprotein IIb/IIIa Receptor Antagonist in Patient with Acute Coronary Syndrome Undergoing Coronary Angioplasty
بواسطة: El-Hammady, Walid Abd-El-Azim منشور: (2002) -
Platelet glycoprotein IIb IIIa polymorphism and sticky platelets in acute coronary syndrome
بواسطة: Asmaa Mohammad Abdelhameed منشور: (2012) -
NON-ST Segment Elevation Acute Coronary Syndrome In Patients With Renal Dysfunction: Benefit Of Low Molecular Weight Heparin With Glycoprotein IIb/IIIa Inhibitors on Outcome Compared To Unfractionated Heparin With Glycoprotein IIb/IIIa Inhibitors
بواسطة: HASSAN MOHAMED, MEDHET منشور: (2007) -
Role of platelet glycoprotein IIb/IIIa receptor blocker (tirofiban) in improving the outcome of stenting difficult or complex coronary artery lesions
بواسطة: Mohamed, Mohamed Helmy منشور: (2003) -
Impact of Glycoprotein IIb/IIIa Inhibition on QT Dispersion After Successful Percutaneous Coronary Intervention
بواسطة: Fahmy،Ahmed Galal AbdEl Fattah منشور: (2008)